21.8 C
New York
Monday, June 15, 2026

Tag: bone

newssourceFORcompanyinformationcontent1marketreleases

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

– Absence of neurotoxicity of any grade in low-volume disease to-date –

June in Review: 14 Top Health Press Releases

A roundup of the most newsworthy healthcare press releases from PR Newswire, including a nasal spray for sleep apnea, a landmark study in clinical...

Chinese Orthodontic Expertise Featured in JAO’s Coverage of DGAO 2024

------Professor Gang Shen's Mandibular Repositioning Protocol Highlighted in JAO's Summary of Leading Presentations at the German Aligner Congress COLOGNE, Germany, July 11, 2025 /PRNewswire/ -- The Journal...

The J.M. Smucker Co. Announces the Planned Retirement of Gail Hollander, Chief Marketing Officer

ORRVILLE, Ohio, July 10, 2025 /PRNewswire/ -- The J.M. Smucker Co. (NYSE: SJM) today announced the planned retirement of Gail Hollander, Chief Marketing Officer, effective...

Global Orthodontists Gather in Europe to Explore Smartee’s Breakthrough in Mandibular Repositioning

Orthodontists Gather in Brussels and Rome to Explore Advances in Malocclusion Treatment with GS Technology ROME, July 10, 2025 /PRNewswire/ -- Smartee hosted two European...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Data from Orbit and Cosmic studies expected around the end of the year 
Data from Orbit and Cosmic studies expected around the end of the year

NativePath Launches Most Effective Activated Charcoal Yet—1,000mg Coconut-Shell Formula for Daily Gut Health

As consumer interest in the best activated charcoal grows, NativePath introduces a clean-label, high-purity formula derived from coconut shells to support bloating, gas, and digestive detox. 
As consumer interest in the best activated charcoal grows, NativePath introduces a clean-label, high-purity formula derived from coconut shells to support bloating, gas, and digestive detox.

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

CARLSBAD, Calif., July 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities...

Native Creatine Responds to 2025 Surge in Creatine Interest Among Women Over 50 Seeking Non-Gym Solutions

NativePath’s Clean-Label Creatine Powder Combines L-Leucine, L-Carnitine, and Creatine Monohydrate for Daily Muscle and Energy Support Without Resistance Training 
NativePath’s Clean-Label Creatine Powder Combines L-Leucine, L-Carnitine, and Creatine Monohydrate for Daily Muscle and Energy Support Without Resistance Training

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...

Luma Nutrition Magnesium Glycinate Surpasses 10,000 Monthly Sales on Amazon

Los Angeles, CA , July 07, 2025 (GLOBE NEWSWIRE) -- Luma Nutrition is proud to announce that its flagship product, Luma Nutrition Magnesium Glycinate 1000mg, has officially surpassed 10,000 units sold per month on Amazon. As one of the best magnesium glycinate supplements available in 2025, this high-absorption formula continues to earn praise for its purity, effectiveness, and ability to support restful sleep, mental clarity, and full-body relaxation. 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBone

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers